STRESS DEGRADATION STUDIES AND DEVELOPMENT OF A VALIDATED RP-HPLC METHOD FOR DETERMINATION OF TIAGABINE IN PRESENCE OF ITS DEGRADATION PRODUCTS

  • Rajakumari Rajasingam International Medical University
  • Sreenivasa Rao Sagineedu Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), 126 Jalan Jalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
  • Yee Hon Tan International Medical University
  • Jeyashanthini Nalaiya Innovax Sdn. Bhd., Jalan Saudaga
  • Mallikarjuna Rao Pichika International Medical University

Abstract

Objective: To develop a simple and rapid isocratic reversed-phase high-performance liquid chromatography (RP-HPLC) method and validate as per ICH and USP guidelines for analysis of tiagabine in the presence of its degradation products.

Methods: The chromatographic separation was achieved on a Vision HT C18 column (150 mm × 4.6 mm, 5 µm) with mobile phase comprising of 11.5 mM of sodium dihydrogen phosphate (adjusted to pH 2.0 with orthophosphoric acid):acetonitrile (50:50,v/v) at a flow rate of 1.0 ml/min and the UV detection wavelength set at 254 nm. Stress degradation studies were performed as stated in ICH guidelines on tiagabine bulk drug using acid, base, oxidation, heat and light.

Results: Tiagabine was found to degrade under acidic, photolytic, oxidative and thermal conditions, but stable under basic hydrolysis condition. The developed method was found to be linear in the concentration range of 50-150 µg/ml (r2= 0.9983) and the percentage recovery for the accuracy was 98.86%-99.35%. The LOD and LOQ obtained were 31.93 µg/ml and 96.76 µg/ml, respectively while the %RSD for precision, robustness, and stability studies were less than 2%. The degradation products formed from the stress study were well separated from tiagabine and hence the method could be regarded as stability indicating.

Conclusion: A simple and rapid RP-HPLC method was developed and validated for analysis of tiagabine in the presence of its degradation products and thus, the proposed method can be used in the analysis of tiagabine bulk drug and pharmaceutical formulation in quality control laboratories.

 

Keywords: Tiagabine, RP-HPLC, Stress degradation studies, Validation

Downloads

Download data is not yet available.

References

1. Mengel H. Tiagabine. Epilepsia 1994;35:S81-4.
2. Sommerville KW, Collins SD. Tiagabine: Chemistry, Bio-transformation, and Pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E. editors. Antiepileptic drugs. 5th ed. USA: Lippincott Williams and Wilkins; 2002. p. 681-90.
3. United States Pharmacopeia. United States Pharmacopoeial Convention. Inc: Rockville MD; 2013. p. 5385-7.
4. Roux HM, Skiba M, Sughir A, Skiba ML, Chanu FO, Levacher V, et al. Identification of tiagabine degradation products using liquid chromatography with electrospray ionization multistage mass spectrometry and ultra‐performance liquid chromatography/ high‐resolution mass spectrometry. Rapid Commun Mass Spectrom 2012;26:287-96.
5. Nahata MC, Morosco RS. Stability of tiagabine in two oral liquid vehicles. Am J Health-Syst Pharm 2003;60:75-7.
6. Azar NJ, Bassel W, Khalil A. Tiagabine. In: Panayiotopoulos CP. editor. Atlas of epilepsies. 1st ed. UK: Springer; 2010. p. 1849-55.
7. Rustum AM, Estrada V. Separation and quantitation of the S-(+)-enantiomer in the bulk drug tiagabine• HCl by chiral high-performance liquid chromatography using a Chiralcel-OD column. J Chromatogr B Biomed Sci Appl 1998;705:111-7.
8. Rustum A, Menon G, Patel S. Separation of the S (+) andR (−)-enantiomers of tiagabine• HCl and its two chiral precursors by chiral chromatography: application to chiral inversion studies. J Pharm Biomed Anal 1998;17:1439-47.
9. Chollet D, Castella E, Goumaz L, Anderegg G. Gas chromatography–mass spectrometry assay method for the therapeutic drug monitoring of the antiepileptic drug tiagabine. J Pharm Biomed Anal 1999;21:641-6.
10. Patil S, Asema SU, Mirza S, Zaheer A, Farooqui M. Method development and validation for quantitative analysis of Tiagabine HCl by ultraviolet spectrophotometry. Int J Chem Sci 2008;6:413-6.
11. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Stability Testing of New Drug Substances and Products ICH Q1A (R2); 2003.
12. Blessy M, Patel RD, Prajapati PN, Agrawal Y. Development of forced degradation and stability indicating studies of drugs-a review. J Pharm Anal 2014;4:159-65.
13. Shinde NG, Bangar BN, Deshmukh SM, Sulake SP, Sherekar DP. Pharmaceutical forced degradation studies with regulatory consideration. Asian J Res Pharm Sci 2013;3:178-88.
14. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Text and Methodology ICH Q2 (R1); 2005.
15. Synder LR, Kirkland JJ, Glajch JL. Practical HPLC Method Development. 2nd ed. Canada: John Wiley and Sons, Inc; 1998.
16. Advanced USP Method. USA: Phenomenex; 2003. Available from http://www.fortunesci.com/image/download2/USER%20GUIDE/ADVANCE%20USP%20methods.pdf. [Last accessed on 20 Dec 2014].
Statistics
470 Views | 911 Downloads
How to Cite
Rajasingam, R., S. R. Sagineedu, Y. H. Tan, J. Nalaiya, and M. R. Pichika. “STRESS DEGRADATION STUDIES AND DEVELOPMENT OF A VALIDATED RP-HPLC METHOD FOR DETERMINATION OF TIAGABINE IN PRESENCE OF ITS DEGRADATION PRODUCTS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 1, Nov. 2015, pp. 230-6, https://innovareacademics.in/journals/index.php/ijpps/article/view/4706.
Section
Original Article(s)